Cold type haemolytic anaemia is a rare blood condition where the immune system mistakenly destroys red blood cells in response to cold temperatures, causing symptoms ranging from mild fatigue to serious complications that affect quality of life and require careful medical management.

How Treatment Approaches Address This Complex Condition

Treatment for cold type haemolytic anaemia focuses on reducing the destruction of red blood cells, managing symptoms like fatigue and circulation problems, and improving a person’s ability to function in daily life. The main goals include controlling the immune system’s attack on healthy blood cells, preventing complications like heart problems or blood clots, and helping patients maintain comfortable lives despite the challenges of avoiding cold temperatures.^[1]

The approach to treatment depends heavily on how severe the condition is and what might be causing it. Some people with very mild symptoms may need only to make lifestyle adjustments, like avoiding cold weather and dressing warmly. Others with more serious disease require medications that calm down the overactive immune system or block specific parts of the body’s defense mechanisms that are causing harm. Because cold type haemolytic anaemia can occur on its own or develop as a result of other health problems like infections, blood cancers, or autoimmune diseases, doctors must consider whether treating an underlying condition might help resolve the anaemia.^[2][3]

The disease can be either short-term or long-lasting. When it occurs after an infection, especially in children, it often goes away on its own once the infection clears. However, primary cold agglutinin disease in adults is typically a chronic condition that requires ongoing management. Understanding which type a patient has helps doctors decide on the most appropriate treatment strategy and predict how long therapy might be needed.^[4]

Standard Medical Treatments Currently in Use

For many patients with cold type haemolytic anaemia, the first and most important treatment is simply avoiding cold exposure. This means wearing appropriate clothing, keeping the home warm, avoiding cold foods and beverages, and even wearing gloves when taking items out of the refrigerator or freezer. For patients with mild disease, these protective measures may be enough to prevent symptoms and maintain adequate red blood cell counts without needing medications. Special protective clothing becomes necessary for those who experience severe reactions even to mild cold temperatures.^[6]

When symptoms become more troublesome or the anaemia becomes severe enough to affect health and quality of life, medications become necessary. Rituximab, a drug that targets a protein called CD20 on certain immune cells, has become the most widely accepted first-line medication for cold agglutinin disease, even though it has not been formally approved for this specific use in many countries. Rituximab works by reducing the number of B cells, which are the immune cells that produce the harmful antibodies attacking red blood cells.^[6][4]

In studies of rituximab treatment, approximately half of patients showed some improvement in their condition, though complete elimination of the disease was rare. When patients do respond to rituximab, the benefits typically last anywhere from two months to more than three years, with most people experiencing relief for about six to eleven months. The medication is usually given as an infusion once a week for four weeks. Patients typically do not see immediate results, as the drug works gradually over several weeks to reduce antibody production.^[6][4]

For patients who are otherwise healthy but have severe disease, doctors may combine rituximab with another medication called bendamustine, which is a type of chemotherapy drug. Bendamustine works by killing rapidly dividing cells, including the abnormal immune cells producing harmful antibodies. The combination of rituximab and bendamustine improves response rates compared to rituximab alone, meaning more patients see their blood counts improve and their symptoms lessen. However, this combination also causes more side effects, which must be balanced against the potential benefits.^[6][4][7]

Corticosteroids like prednisone, which are commonly used to treat other types of autoimmune anaemia, generally do not work well for cold type haemolytic anaemia. The antibodies involved in this condition, called IgM antibodies, do not respond to steroids the way IgG antibodies do in warm autoimmune haemolytic anaemia. Occasionally, some patients may show improvement with steroids, but those who do often need unacceptably high doses to maintain that improvement, leading to significant side effects from long-term steroid use.^[6][9]

When patients experience severe, sudden drops in red blood cell counts, they may need red blood cell transfusions to quickly restore oxygen-carrying capacity and prevent dangerous complications. These transfusions must be given carefully, with the blood warmed before administration to prevent the cold antibodies from attacking the transfused cells. Transfusions are typically reserved for emergency situations or very severe anaemia because they carry risks and only provide temporary relief.^[6][4]

Some patients also receive folic acid supplements, typically one milligram daily. Because red blood cells are being destroyed faster than normal, the body uses up folic acid more quickly trying to make replacements. Supplementing with folic acid helps prevent a type of anaemia caused by folic acid deficiency from developing on top of the autoimmune anaemia.^[9]

Innovative Therapies Being Tested in Clinical Trials

Recent scientific understanding of how cold type haemolytic anaemia works at the molecular level has opened doors to exciting new treatment possibilities. Researchers now know that a part of the immune system called the complement system plays a crucial role in destroying red blood cells in this disease. The complement system is a cascade of proteins that, when activated by the cold antibodies attached to red blood cells, punches holes in the cells and marks them for destruction. This knowledge has led to the development of drugs that block specific steps in this destructive process.^[4][7]

The most significant recent advancement is sutimlimab, a complement inhibitor that was approved by the United States Food and Drug Administration in 2022. Sutimlimab works by selectively targeting and blocking a protein called C1s, which is one of the early components in the complement cascade. By blocking C1s, sutimlimab prevents the entire destructive complement process from getting started, even though the cold antibodies are still attaching to red blood cells.^[6][14]

Sutimlimab is specifically indicated to decrease the need for red blood cell transfusions in patients with haemolysis associated with cold agglutinin disease. In clinical trials, patients receiving sutimlimab experienced improvements in their red blood cell counts and haemoglobin levels, along with reductions in markers of red blood cell destruction. Many patients also reported improvements in fatigue and other symptoms that had been limiting their daily activities. The drug is given as an infusion, and because it targets a specific step in the disease process rather than broadly suppressing the immune system, it may have fewer side effects than traditional immunosuppressive medications.^[6]

Another complement inhibitor that has been studied in small trials is eculizumab. Unlike sutimlimab, which blocks an early step in the complement cascade, eculizumab blocks a later step by inhibiting a protein called C5. While eculizumab has shown benefit in some patients with cold agglutinin disease, it appears to work better in certain situations than others, depending on exactly how the complement system is being activated in each individual patient. Research continues to determine which patients might benefit most from eculizumab versus other complement-blocking drugs.^[6]

Clinical trials have also explored the use of daratumumab, an antibody that targets a different immune cell protein called CD38. Daratumumab is already approved for treating multiple myeloma, a blood cancer, but researchers discovered it might also help patients with cold agglutinin disease. The drug works by killing plasma cells, which are mature immune cells that produce antibodies. By reducing the number of plasma cells, daratumumab can decrease the production of the harmful cold antibodies. Case reports and one small trial have described patients with cold agglutinin disease that did not respond to other treatments showing improvement with daratumumab.^[6][14]

Beyond complement inhibition and plasma cell targeting, researchers continue to investigate other approaches to managing cold type haemolytic anaemia. Some studies have looked at combining rituximab with different chemotherapy drugs besides bendamustine, such as fludarabine, to find combinations that might work better or cause fewer side effects. Others are exploring whether drugs that target different parts of the B-cell development pathway might offer advantages over current treatments.^[6][4]

The advantage of many newer treatments being tested in clinical trials is that they target specific molecular pathways involved in the disease rather than broadly suppressing the entire immune system. This targeted approach may lead to fewer infections and other complications compared to traditional immunosuppressive therapy. However, these treatments are still being studied to fully understand their long-term safety and effectiveness, which is why they remain in clinical trials or have only recently been approved for use.^[4][7]

Most common treatment methods

• Protective measures against cold
  • Wearing warm clothing including hats, gloves, and layered garments
  • Avoiding cold food and beverages
  • Keeping indoor environments warm
  • Using gloves when handling refrigerated items
  • Limiting time outdoors in cold weather
• Immunotherapy with rituximab
  • First-line medication targeting CD20 protein on B cells
  • Given as weekly infusions for four weeks
  • Approximately 50% of patients show partial response
  • Response typically lasts 6 to 11 months
  • May be combined with bendamustine in severe cases
• Complement inhibition
  • Sutimlimab blocks C1s protein to prevent complement activation
  • Approved by FDA in 2022 to reduce transfusion needs
  • Eculizumab blocks C5 protein in complement cascade
  • Targets specific molecular pathways in disease process
• Chemotherapy combinations
  • Rituximab combined with bendamustine for severe disease
  • Rituximab with fludarabine in some treatment protocols
  • Improves response rates but increases side effects
  • Reserved for patients with significant disease burden
• Red blood cell transfusions
  • Used for severe, acute drops in red blood cell counts
  • Blood must be warmed before administration
  • Provides temporary relief in emergency situations
  • Helps prevent dangerous complications from severe anaemia
• Plasma cell-directed therapy
  • Daratumumab targets CD38 protein on plasma cells
  • Reduces production of harmful cold antibodies
  • Tested in clinical trials for refractory disease
  • Case reports show benefit in difficult-to-treat patients
• Supportive care
  • Folic acid supplementation at 1 mg daily
  • Prevents folic acid deficiency from increased red cell production
  • Treatment of underlying infections if present
  • Management of complications like blood clots

Understanding Treatment Duration and Monitoring

The length of treatment for cold type haemolytic anaemia varies considerably depending on whether the condition is primary or secondary, how severe it is, and how well it responds to therapy. For secondary cold agglutinin disease caused by infections, treatment may only be needed until the infection clears, which can be a matter of weeks to months. In children, who typically develop cold type haemolytic anaemia after infections, the condition is often self-limited and requires mainly supportive care rather than long-term medication.^[4][7]

Primary cold agglutinin disease in adults is usually a chronic condition requiring ongoing management. Patients receiving rituximab may need repeat treatments when the disease becomes active again, which typically occurs months to years after the initial therapy. The decision about when to retreat depends on symptoms returning, blood counts dropping, or laboratory tests showing increased destruction of red blood cells. Some patients may go through periods of remission where they need no active treatment beyond cold avoidance, while others require more continuous therapy.^[3][6]

Long-term monitoring is essential for all patients with cold type haemolytic anaemia. Regular blood tests check haemoglobin levels, markers of red blood cell destruction like bilirubin and lactate dehydrogenase, and reticulocyte counts which show how hard the bone marrow is working to replace destroyed cells. Doctors also monitor for complications such as blood clots, heart problems, and infections, especially in patients receiving medications that suppress the immune system. Patients on complement inhibitors need ongoing monitoring to ensure the treatment continues working and to watch for any emerging side effects.^[3][6]

Living with Cold Type Haemolytic Anaemia

Managing daily life with cold type haemolytic anaemia requires constant awareness of temperature and taking protective measures that may feel burdensome at times. Simple activities that others take for granted, like going grocery shopping or spending time outside in winter, require careful planning. Patients often need to warm their cars before entering them, dress in multiple layers even for short outdoor trips, and avoid swimming in cool water or drinking cold beverages. Some people find they need to avoid certain occupations or activities that involve cold exposure.^[1][5]

The fatigue caused by anaemia can significantly impact quality of life, making it difficult to work full-time, care for family members, or participate in social activities. Many patients describe feeling exhausted after minimal exertion and needing frequent rest periods throughout the day. This chronic tiredness is not just being sleepy—it is a profound lack of energy that affects physical and mental functioning. As treatment improves red blood cell counts, many patients notice substantial improvements in their energy levels and ability to function.^[1][5]

Psychological support is important for people living with cold type haemolytic anaemia. The stress of managing a chronic condition, dealing with unpredictable symptom flares, and making constant adjustments to avoid cold can take an emotional toll. Support groups, either in-person or online, allow patients to connect with others who understand the unique challenges of this rare disease. Mental health professionals can help patients develop coping strategies for managing anxiety about their condition and adapting to lifestyle limitations.^[5]

Educating family members, employers, and friends about the condition helps create understanding and support. Many people have never heard of cold type haemolytic anaemia and may not realize why someone cannot tolerate cold temperatures that seem only mildly cool to others, or why they need to avoid certain activities. Having written information from healthcare providers to share can help explain the medical basis for necessary accommodations at work or modifications to social plans.^[1][5]